$PPCB
Propanc Biopharma Inc

2021 Q4 Form 10-Q Financial Statement

#000149315222004382 Filed on February 14, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2020 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $352.7K $223.9K
YoY Change 57.51% -83.81%
% of Gross Profit
Research & Development $50.75K
YoY Change
% of Gross Profit
Depreciation & Amortization $500.00 $500.00
YoY Change 0.0% -20.63%
% of Gross Profit
Operating Expenses $403.5K $274.1K
YoY Change 47.2% -80.19%
Operating Profit -$403.5K
YoY Change
Interest Expense -$452.0K -$129.6K
YoY Change 248.88% -74.27%
% of Operating Profit
Other Income/Expense, Net -$452.0K
YoY Change
Pretax Income -$855.4K -$403.6K
YoY Change 111.93% -78.38%
Income Tax -$55.46K $0.00
% Of Pretax Income
Net Earnings -$800.0K -$403.6K
YoY Change 98.19% -78.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$16.20K -$448.2K
COMMON SHARES
Basic Shares Outstanding 49.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.62K $21.24K
YoY Change 246.61% 76.71%
Cash & Equivalents $73.62K
Short-Term Investments
Other Short-Term Assets $5.640K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $84.88K $23.18K
YoY Change 266.18% 11.5%
LONG-TERM ASSETS
Property, Plant & Equipment $3.120K $15.12K
YoY Change -79.37% -64.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $22.18K $2.310K
YoY Change 860.17% 9.48%
Total Long-Term Assets $25.30K $17.44K
YoY Change 45.07% -60.93%
TOTAL ASSETS
Total Short-Term Assets $84.88K $23.18K
Total Long-Term Assets $25.30K $17.44K
Total Assets $110.2K $40.62K
YoY Change 171.25% -37.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $920.7K $1.020M
YoY Change -9.69% 23.3%
Accrued Expenses $838.9K $1.306M
YoY Change -35.76% 38.17%
Deferred Revenue
YoY Change
Short-Term Debt $1.026M $1.266M
YoY Change -18.93% -57.6%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.040M $3.649M
YoY Change -16.67% -36.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.040M $3.649M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.040M $3.649M
YoY Change -16.67% -36.41%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.930M -$3.608M
YoY Change
Total Liabilities & Shareholders Equity $110.2K $40.62K
YoY Change 171.25% -37.92%

Cashflow Statement

Concept 2021 Q4 2020 Q4
OPERATING ACTIVITIES
Net Income -$800.0K -$403.6K
YoY Change 98.19% -78.38%
Depreciation, Depletion And Amortization $500.00 $500.00
YoY Change 0.0% -20.63%
Cash From Operating Activities -$224.3K -$261.0K
YoY Change -14.06% -37.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 354.5K 200.0K
YoY Change 77.25% -24.53%
NET CHANGE
Cash From Operating Activities -224.3K -261.0K
Cash From Investing Activities
Cash From Financing Activities 354.5K 200.0K
Net Change In Cash 130.2K -61.03K
YoY Change -313.29% -59.73%
FREE CASH FLOW
Cash From Operating Activities -$224.3K -$261.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
USD
CY2021Q2 us-gaap Deferred Costs
DeferredCosts
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
PPCB Common Stock Issued For Deferred Offering Cost
CommonStockIssuedForDeferredOfferingCost
USD
PPCB Prepaid Common Stock Issued For Services
PrepaidCommonStockIssuedForServices
USD
PPCB Prepaid Common Stock Issued For Services
PrepaidCommonStockIssuedForServices
USD
PPCB Reversal Of Common Stock Issuable And Put Premium Due To Cancellation Of Conversions Of Convertible Debt And Accrued Interest
ReversalOfCommonStockIssuableAndPutPremiumDueToCancellationOfConversionsOfConvertibleDebtAndAccruedInterest
USD
us-gaap Stock Issued1
StockIssued1
USD
PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1
DeemedDividendUponAlternateCashlessExerciseOfWarrants1
USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2021Q4 PPCB Common Stock Issuable
CommonStockIssuable
USD
PPCB Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021Q2 PPCB Common Stock Issuable
CommonStockIssuable
USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
USD
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
USD
CY2021Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2020Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
CY2020Q4 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
USD
CY2020Q4 PPCB Issuance Of Common Stock For Alternate Cashless Exercise Of Warrants
IssuanceOfCommonStockForAlternateCashlessExerciseOfWarrants
USD
CY2020Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
USD
CY2020Q4 PPCB Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
USD
CY2021Q3 PPCB Issuance Of Common Stock For Alternate Cashless Exercise Of Warrants
IssuanceOfCommonStockForAlternateCashlessExerciseOfWarrants
USD
CY2021Q3 PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants
DeemedDividendUponAlternateCashlessExerciseOfWarrants
USD
CY2021Q4 PPCB Issuance Of Common Stock For Alternate Cashless Exercise Of Warrants
IssuanceOfCommonStockForAlternateCashlessExerciseOfWarrants
USD
CY2021Q4 PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants
DeemedDividendUponAlternateCashlessExerciseOfWarrants
USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
USD
PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
shares
PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2021Q4 PPCB Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding
USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
PPCB Weighted Average Fair Value Of Options Granted During Period
WeightedAverageFairValueOfOptionsGrantedDuringPeriod
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD

Files In Submission

Name View Source Status
0001493152-22-004382-index-headers.html Edgar Link pending
0001493152-22-004382-index.html Edgar Link pending
0001493152-22-004382.txt Edgar Link pending
0001493152-22-004382-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
ppcb-20211231.xsd Edgar Link pending
ppcb-20211231_cal.xml Edgar Link unprocessable
ppcb-20211231_def.xml Edgar Link unprocessable
ppcb-20211231_lab.xml Edgar Link unprocessable
ppcb-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending